Name: 글로벌 시장 동향
SKU: CD4124
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 중증 복합 면역결핍증(SCID) 진단 시장은 2022년 1억 9,650만 달러 규모에 도달했으며, 2030년까지 4억 2,350만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 중증 복합 면역결핍증(SCID) 진단 시장은 예측 기간(2023~2030년) 동안 연평균 10.4%의 성장률을 기록할 것으로 예상됩니다. 기술 발전과 신제품 개발에 대한 투자 증가가 중증 복합 면역결핍증(SCID) 진단 시장 수요 증가를 견인하고 있습니다.
중증 복합 면역결핍증(SCID) 진단을 위해서는 일반적으로 아동의 철저한 병력 청취와 신체검사가 필요합니다. 진단 확인을 위해 총 혈구 수와 같은 추가적인 혈액 검사가 필요할 수 있습니다. 신제품 출시와 면역결핍증 환자 수 증가는 전 세계 중증 복합 면역결핍증(SCID) 진단 시장 성장을 이끄는 주요 요인입니다.

중증 복합 면역결핍증(SCID) 진단 시장은 TREC, 전혈구 검사(CBC), 유전자 검사, 생화학 검사 등 다양한 검사 유형을 포함하며, 이러한 검사 유형들이 SCID 진단 시장 점유율 증가에 기여하고 있습니다. 전 세계 SCID 진단 시장은 연구 개발 증가와 각국의 신약 승인 예정 등 여러 요인으로 인해 성장하고 있으며, 이는 SCID 진단 시장 성장에 긍정적인 전망을 제시하고 있습니다.

시장 동향
진단 절차에 대한 인식 증가가 SCID 진단 시장 성장을 견인
SCID는 일반적으로 신생아 출생 직후에는 임상적으로 나타나지 않습니다. 이는 SCID 신생아가 생후 몇 주 동안 다른 사람의 항체로부터 면역력을 형성하며 생존하기 때문입니다. 하지만 시간이 지나면서 아기들은 면역 반응이 부족하기 때문에 소아마비, 수두, 로타바이러스, BCG 백신 등에 포함된 약화된 미생물에 의해 영향을 받게 됩니다.
SCID는 일반적으로 증상이 처음 나타난 후 생후 4~6개월 사이에 진단됩니다. 가족력이 있는 경우, 조기 개입을 통해 태아의 DNA 염기서열 분석을 통해 관련 유전자 변이를 확인할 수 있습니다.
임신 중 SCID를 조기에 발견하면 산후 치료를 위한 충분한 시간을 확보할 수 있습니다. 그다음으로 좋은 방법은 신생아 선별 검사입니다. 출생 시 혈액을 채취하여 B세포와 T세포를 확인하고 그 역할을 파악할 수 있습니다. 보다 포괄적인 진단을 위해서는 출생 후 DNA 검사를 활용할 수 있습니다.

중증 복합 면역결핍증(SCID) 발병률 증가로 제약회사에 수익성 높은 기회가 창출되고 있습니다.
아데노신 탈아미나제 결핍증은 전 세계적으로 20만 명에서 100만 명당 1명꼴로 발생하는 매우 드문 질환입니다. SCID 사례의 약 15%가 이 질환으로 인해 발생합니다. SCID(중증 복합 면역결핍증)는 생명을 위협하는 자가면역 이상을 유발하는 드문 유전 질환입니다. 이는 어떤 면에서는 주요 면역학적 증상입니다.
미국에서는 매년 신생아 5만 8천 명 중 1명이 SCID를 가지고 태어납니다. 중증 복합 면역결핍증(SCID)은 소아에서 흔히 나타나며 심각한 면역 기능 저하를 초래하여 신체가 작은 감염조차 이겨낼 수 없게 만듭니다. 이는 가장 심각한 PIDD로 간주됩니다.

SCID의 다른 유형은 다양한 유전 질환과 아데노신 데아미나제 효소 결핍으로 인해 발생합니다. SCID를 앓는 영아는 건강한 신생아에게 나타나는 일반적인 질병에 걸리기 쉽습니다. 그러나 이들은 일반적으로 건강한 면역 체계를 가진 아이들에게는 안전한 미생물이나 생백신으로 인한 질병에 더 취약합니다.
진단 지연 및 부적절한 진단은 시장 성장을 저해할 것입니다.
하지만 가족력 부재, 뚜렷한 신체적 특징의 부재, 기타 요인으로 인해 일반 소아에서도 감염이 빈번하게 발생합니다. 안타깝게도 환자가 여러 차례 심각한 질병을 앓았을 때, 의료진은 단순히 면역 체계 약화 가능성만을 고려하는 경우가 많습니다.
슬프게도, 아픈 누나나 다른 SCID 환자 가족력이 없는 영아는 여러 차례 감염이 발생한 후에야 진단되는 경우가 흔합니다. 이러한 감염은 응급 치료, 가족의 고통, 장기적인 질병 부담에 큰 영향을 미치며, 드물게는 사망에 이르기도 합니다.

COVID-19 영향 분석
COVID-19 팬데믹과 전 세계 여러 국가의 봉쇄 조치로 인해 모든 산업 분야 기업의 재정 건전성이 영향을 받았습니다. 이에 따라 COVID-19 보건 비상 사태 기간 동안 미국 식품의약국(FDA)은 임상시험 참여자의 안전 확보, 임상시험 관리 기준(GCP) 준수, 임상시험의 무결성 위험 최소화 등을 포함하여 스폰서와 연구자를 지원하는 일반적인 고려 사항을 담은 가이드라인을 발표했습니다.
러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 중증 복합 면역결핍증(SCID) 진단 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재 수출입은 예측 기간 동안 전 세계 중증 복합 면역결핍증(SCID) 진단 시장 성장에 거의 영향을 미치지 않을 것으로 전망됩니다.
세분화 분석
전 세계 중증 복합 면역결핍증(SCID) 진단 시장은 질병 유형, 검사 유형, 최종 사용자 및 지역별로 세분화됩니다.

검사 유형 부문에서 TREC가 장점 증가에 힘입어 시장 점유율 32.8%를 차지하고 있습니다.
거스리 카드 건조 혈액 반점(DBS)에서 T세포 수용체 절제 원(TREC)은 실시간 정량 중합효소 연쇄 반응(RT-qPCR)을 사용하여 정량화할 수 있으며, 이를 통해 SCID를 조기에 진단할 수 있습니다. TREC 수치가 낮으면 T세포 수용체 재조합의 DNA 결과이므로 T세포 림프종(TCL)을 나타냅니다.
따라서 신생아의 TREC 수치를 이용하여 T세포 발달 결함을 식별함으로써 SCID를 선별할 수 있습니다. 선별 검사에서 양성 반응이 나온 후에는 정확한 유전적 진단을 확인하고 환자가 전형적인 SCID인지 아니면 다른 유형의 TCL인지 확인하기 위해 추가 진단 검사가 필요합니다.
SCID와 관련된 증상의 심각성, 조기 진단 후 개선된 예후, 선별 검사의 접근성, 그리고 SCID 신생아 선별 검사(NBS)의 경제적 타당성 입증은 모두 SCID가 윌슨-융너 선별 검사 기준을 충족하며 SCID가 NBS에 적합한 대상임을 보여줍니다.

지리적 분석
북미는 주요 업체들의 강력한 입지와 중증 복합 면역결핍증(SCID) 진단 기술의 발전으로 전체 시장 점유율의 약 43.5%를 차지했습니다.
제조업체들은 북미 지역의 SCID 진단 기술 발전과 수요 증가로 인해 사업 확장의 기회를 얻고 있습니다. 북미에는 많은 생산 업체와 공급업체가 있으며, 빠른 경제 성장으로 SCID 진단 관련 산업 생산이 증가하여 수요 증가를 견인하고 있습니다.
북미에는 많은 제조업체와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되면서 신제품 연구 개발에 대한 수요가 증가하고 있습니다.
새로운 연구 개발 기술이 등장함에 따라 시장은 더욱 성장할 것입니다. 기술 발전, 정부 승인, 신제품 출시 등이 모두 시장 성장에 기여하고 있습니다. 사람들은 새로운 기기와 기술에 대한 인식이 높아지고 있으며, 이는 북미 시장 확대를 촉진하고 있습니다. 이러한 요인들이 북미 시장의 지배력을 뒷받침하고 있습니다.

경쟁 환경
중증 복합 면역결핍증(SCID) 진단 시장의 주요 글로벌 업체로는 ARCHIMED Life Science GmbH, Revvity (PerkinElmer), Labsystems Diagnostics Oy, Revcovi, LaCAR MDx, Leadiant Biosciences, Inc., Winfertility, GSK Plc, CSL Behring, Devyser Diagnostics 등이 있습니다.
보고서 구매 이유

• 질병 유형, 검사 유형, 최종 사용자 및 지역별 글로벌 중증 복합 면역결핍증(SCID) 진단 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 중증 복합 면역결핍증(SCID) 진단 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

글로벌 중증 복합 면역결핍증(SCID) 진단 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Severe Combined Immunodeficiency (SCID) Diagnosis Market reached US$ 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 423.5 million by 2030. The global severe combined immunodeficiency (SCID) diagnosis market is expected to exhibit a CAGR of 10.4% during the forecast period (2023-2030). The increasing technological advancements and the growing investments for novel products are driving up demand for severe combined immunodeficiency (SCID) diagnosis market trends.
To identify severe combined immunodeficiency (SCID), a thorough medical history plus physical examination of the child are typically required. Additional blood tests, such as a total blood cell count, could be requested in order to verify the diagnosis. The launch of new products, and an increase in patients with immunodeficiency are the main factors propelling the global market for severe combined immunodeficiency (SCID) diagnosis.
The severe combined immunodeficiency (SCID) diagnosis market scope comprises test type as TREC, complete blood count (CBC), genetic test, biochemical test, others, which has increased the severe combined immunodeficiency (SCID) diagnosis market share. The global market for severe combined immunodeficiency (SCID) diagnosis is expanding as a result of factors including the increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the severe combined immunodeficiency (SCID) diagnosis market growth.
Market Dynamics
Increased Awareness of Diagnosis Procedures Drives the Growth of the Severe Combined Immunodeficiency (SCID) Diagnosis Market
SCID typically does not manifest clinically right away when a baby is born. This is due to the fact that preferably for the first few weeks, newborns with SCID live on developing immunity from mthe other's antibodies. But over time, babies are nonetheless affected by weakened microorganisms in vaccines like those for polio, chickenpox, rotavirus, BCG, and others because they lack an immune response.
When neonates reach an age between four and six months following the symptoms first appearing, SCID is typically diagnosed. Early intervention, when there is a risk owing to a family record of immunodeficiency might involve DNA sequencing of the fetus to check for any relevant gene changes.
Early detection of SCID during pregnancy allows for plenty of time for postpartum treatment. The next-best choice is newborn screening. Blood can be drawn at birth to identify B cells and T cells and determine their roles. Postnatal testing for DNA can be utilized for a more comprehensive diagnosis.
Increasing Incidence of Severe Combined Immunodeficiency (SCID) Disorder Creates Lucrative Opportunities for Manufacturers
Adenosine deaminase insufficiency is a very uncommon condition that affects only 1 in 200,000 to 1,000,000 babies globally. Around 15% of SCID instances are due to this disorder. An uncommon genetic disorder called SCID (severe combined immunodeficiency) results in life-threatening autoimmune abnormalities. It is a primary immunological symptom in some way.
In the United States, 1 in 58,000 neonates is born having SCID each year. A hereditary primary immunodeficiency disorder (PIDD) called severe combined immunodeficiency (SCID) frequently shows up in children and results in severe immunological insufficiency, leaving the body unable to fight off even small infections. It is considered to be the most severe PIDD.
Other varieties of SCID are caused by a variety of genetic disorders as well as a deficiency in the enzyme adenosine deaminase. Infants having SCID are prone to typical illnesses that affect healthy newborns. They are nonetheless more susceptible to illnesses brought on by microbes or live vaccines, which are typically safe for kids with healthy immune systems.
Delayed and Improper Diagnosis will Hamper the Growth of the Market.
However, infections are frequent in the general population of children due to the absence of a known family history, an absence of differentiating physical characteristics, and other factors. Unfortunately, when a patient has gone through a string of illnesses, most of which are serious, medical professionals only take the possibility of weakness in host defenses into account.
Sadly, infants with SCID who lack an older sister who is sick or another known affected family member are typically not detected until after numerous infections have taken place. These infections always have a significant influence on urgent medical care, family suffering, and long-term morbidity, while they occasionally result in death.
COVID-19 Impact Analysis
The financial health of companies across all industries was impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the interval of the COVID-19 health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global severe combined immunodeficiency (SCID) diagnosis market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global severe combined immunodeficiency diagnosis market growth over the forecast period.
Segment Analysis
The global severe combined immunodeficiency (SCID) diagnosis market is segmented based on disease type, test type, end user and region.
TREC from Test Type Segment Accounts for 32.8% of Market Share Owing to Rising Advantages
In Guthrie card dried blood spots (DBS), T-cell receptor excision circles (TRECs) can be quantified using real-time quantitative polymerase chain reaction (RT-qPCR), which enables early SCID detection. Low TRECs represent TCL since they are a DNA consequence of T cell receptor recombination.
Thus, SCID can be screened for using neonatal TREC levels to identify defective T cell development. After receiving a positive screen, diagnostic testing is necessary to confirm a precise genetic diagnosis and to ascertain whether the patient has typical SCID or another type of TCL.
The severity of the symptoms associated with SCID, the improved prognosis following a timely diagnosis, the accessibility of a screening test, along with proof that newborn screening (NBS) for SCID is financially viable, all serve to show that SCID satisfies the Wilson-Jungner criteria for screening and designate SCID as a suitable candidate for NBS.
Geographical Analysis
North America Accounted for Approximately 43.5% of the Market Share Owing to the Strong Presence of Major Players and the Advancements in Severe Combined Immunodeficiency (SCID) Diagnosis
Manufacturers have chances to expand their operations in this region because of the rising demand for severe combined immunodeficiency (SCID) diagnosis for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of severe combined immunodeficiency diagnosis, which has increased the demand.
There are many manufacturers and suppliers in North America, and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for research and development of novel products.
The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals, and the introduction of new products all contribute to growth. People are becoming more aware of novel instruments and technologies, leading to the expansion of the market in this region. These factors are responsible for the dominance of North America.
Competitive Landscape
The major global players in the severe combined immunodeficiency (SCID) diagnosis market include ARCHIMED Life Science GmbH, Revvity (PerkinElmer), Labsystems Diagnostics Oy, Revcovi, LaCAR MDx, Leadiant Biosciences, Inc., Winfertility, GSK Plc, CSL Behring and Devyser Diagnostics among others.
Why Purchase the Report?
• To visualize the global severe combined immunodeficiency (SCID) diagnosis market segmentation based on disease type, test type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of severe combined immunodeficiency (SCID) diagnosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global severe combined immunodeficiency (SCID) diagnosis market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Test Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increased Awareness of Diagnosis Procedures
4.1.1.2. Increasing Incidence of Severe Combined Immunodeficiency (SCID) Disorder
4.1.2. Restraints
4.1.2.1. Delayed and Improper Diagnosis
4.1.3. Opportunity
4.1.3.1. Rising Research and Development and Novel Product Launches
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. X-linked SCID *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. ADA-SCID
7.4. Others
8. By Test Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
8.1.2. Market Attractiveness Index, By Test Type
8.2. TREC *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Complete blood count (CBC)
8.4. Genetic Test
8.5. Biochemical Test
8.6. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic and Research Laboratories
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. ARCHIMED Life Science GmbH *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Revvity (PerkinElmer)
12.3. Labsystems Diagnostics Oy
12.4. Revcovi
12.5. LaCAR MDx
12.6. Leadiant Biosciences, Inc.
12.7. Winfertility
12.8. GSK Plc
12.9. CSL Behring
12.10. Devyser Diagnostics
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

ARCHIMED Life Science GmbH, 4.	Key Developments, Revvity (PerkinElmer), Labsystems Diagnostics Oy, Revcovi, LaCAR MDx, Leadiant Biosciences, Inc., Winfertility, GSK Plc, CSL Behring, Devyser Diagnostics

표 목록 (Tables)

List of Tables Table 1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 7 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2021-2030 (US$ Million)

Table 9 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 14 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2021-2030 (US$ Million)

Table 15 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 18 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2021-2030 (US$ Million)

Table 19 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2021-2030 (US$ Million)

Table 23 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By Test Type, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, By End User, 2021-2030 (US$ Million)

Table 32 ARCHIMED Life Science GmbH: Overview

Table 33 ARCHIMED Life Science GmbH: Product Portfolio

Table 34 ARCHIMED Life Science GmbH: Key Developments

Table 35 Revvity (PerkinElmer): Overview

Table 36 Revvity (PerkinElmer): Product Portfolio

Table 37 Revvity (PerkinElmer): Key Developments

Table 38 Labsystems Diagnostics Oy: Overview

Table 39 Labsystems Diagnostics Oy: Product Portfolio

Table 40 Labsystems Diagnostics Oy: Key Developments

Table 41 Revcovi: Overview

Table 42 Revcovi: Product Portfolio

Table 43 Revcovi: Key Developments

Table 44 LaCAR MDx: Overview

Table 45 LaCAR MDx: Product Portfolio

Table 46 LaCAR MDx: Key Developments

Table 47 Leadiant Biosciences, Inc.: Overview

Table 48 Leadiant Biosciences, Inc.: Product Portfolio

Table 49 Leadiant Biosciences, Inc.: Key Developments

Table 50 Winfertility: Overview

Table 51 Winfertility: Product Portfolio

Table 52 Winfertility: Key Developments

Table 53 GSK Plc: Overview

Table 54 GSK Plc: Product Portfolio

Table 55 GSK Plc: Key Developments

Table 56 CSL Behring: Overview

Table 57 CSL Behring: Product Portfolio

Table 58 CSL Behring: Key Developments

Table 59 Devyser Diagnostics: Overview

Table 60 Devyser Diagnostics: Product Portfolio

Table 61 Devyser Diagnostics: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Test Type, 2022 & 2030 (%)

Figure 4 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 7 X-linked SCID Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 8 ADA-SCID Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 9 Others Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 10 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Y-o-Y Growth, By Test Type, 2022-2030 (%)

Figure 11 TREC Test Type in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 12 Complete blood count (CBC) Test Type in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 13 Genetic Test Test Type in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 14 Biochemical Test Test Type in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 15 Others Test Type in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 16 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 17 Hospitals End User in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 18 Diagnostic and Research Laboratories End User in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 19 Cancer Care and Research Institutes End User in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 20 Others End User in Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 21 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 23 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 24 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 25 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 26 Middle East and Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 27 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 28 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Disease Type, 2022 & 2030 (%)

Figure 29 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Test Type, 2022 & 2030 (%)

Figure 30 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By End User, 2022 & 2030 (%)

Figure 31 North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 33 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Disease Type, 2022 & 2030 (%)

Figure 34 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Test Type, 2022 & 2030 (%)

Figure 35 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By End User, 2022 & 2030 (%)

Figure 36 South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Country, 2022 & 2030 (%)

Figure 37 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 38 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Disease Type, 2022 & 2030 (%)

Figure 39 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Test Type, 2022 & 2030 (%)

Figure 40 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By End User, 2022 & 2030 (%)

Figure 41 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Country, 2022 & 2030 (%)

Figure 42 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 43 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Disease Type, 2022 & 2030 (%)

Figure 44 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Test Type, 2022 & 2030 (%)

Figure 45 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By End User, 2022 & 2030 (%)

Figure 46 Asia-Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Country, 2022 & 2030 (%)

Figure 47 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Value, 2021-2030 (US$ Million)

Figure 48 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Disease Type, 2022 & 2030 (%)

Figure 49 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By Test Type, 2022 & 2030 (%)

Figure 50 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Share, By End User, 2022 & 2030 (%)

Figure 51 ARCHIMED Life Science GmbH: Financials

Figure 52 Revvity (PerkinElmer): Financials

Figure 53 Labsystems Diagnostics Oy: Financials

Figure 54 Revcovi: Financials

Figure 55 LaCAR MDx: Financials

Figure 56 Leadiant Biosciences, Inc.: Financials

Figure 57 Winfertility: Financials

Figure 58 GSK Plc: Financials

Figure 59 CSL Behring: Financials

Figure 60 Devyser Diagnostics: Financials

글로벌 중증 복합 면역결핍증(SCID) 진단 시장 – 2023-2030

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market -2023-2030